About
City Therapeutics, Inc.
City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules.
The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases across multiple therapeutic areas, including ophthalmologic conditions such as retinal diseases and geographic atrophy.
It designs and engineers RNAi trigger molecules, such as smaller size, novel cleavage mechanisms, and tailored targeting ligands to enhance potency, specificity, and delivery to various tissue types.
City Therapeutics, Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Change from offer price to today
Live Market Snapshot
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:CTY
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-10-30 | $22.08 | $22.26 | $20.37 | $20.71 | $20.71 | -1.37 | 116,800 |
| 2026-10-29 | $21.63 | $22.35 | $21.54 | $22.14 | $22.14 | +0.51 | 130,900 |
| 2026-10-28 | $20.89 | $22.05 | $20.50 | $21.65 | $21.65 | +0.76 | 335,300 |
| 2026-10-27 | $20.79 | $21.59 | $20.70 | $20.86 | $20.86 | +0.07 | 214,800 |
| 2026-10-26 | $20.62 | $21.31 | $20.30 | $20.79 | $20.79 | +0.17 | 136,100 |
| 2026-10-23 | $20.62 | $21.14 | $20.03 | $20.77 | $20.77 | +0.15 | 343,800 |
| 2026-10-22 | $20.41 | $20.88 | $19.75 | $20.77 | $20.77 | +0.36 | 127,600 |
| 2026-10-21 | $20.78 | $21.69 | $19.97 | $20.43 | $20.43 | -0.35 | 283,100 |
| 2026-10-20 | $21.44 | $21.50 | $20.00 | $20.83 | $20.83 | -0.61 | 632,800 |
| 2026-10-19 | $21.94 | $22.00 | $21.03 | $21.46 | $21.46 | -0.48 | 302,400 |
| 2026-10-16 | $23.00 | $23.88 | $20.50 | $22.40 | $22.40 | -0.60 | 1,406,100 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| SCHEDULE 13D | Oct 26, 2026 | Filing |
| SCHEDULE 13G | Oct 26, 2026 | Filing |
| SCHEDULE 13G | Oct 22, 2026 | Filing |
| 8-K | Oct 19, 2026 | Current Report |
| S-8 | Oct 16, 2026 | Securities to be offered to employees in employee benefit plans |
| 424B4 | Oct 16, 2026 | Prospectus |
| EFFECT | Oct 15, 2026 | Notice of Effectiveness |
| S-1MEF | Oct 15, 2026 | Registration adding securities to prior Form S-1 registration |
| CERT | Oct 15, 2026 | Certification by an exchange approving securities for listing |
| 8-A12B | Oct 13, 2026 | Registration of securities |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Andrew (Andy) Orth, M.B.A.
President, Chief Executive Officer and Director
Keith Regnante, M.B.A.
Chief Financial Officer
Baisong Mei, M.D., Ph.D.
Chief Medical Officer
Tracy Zimmermann, Ph.D.
Chief Scientific Officer
Sebastian Trousil, Ph.D.
Chief Operating Officer
John Maraganore, Ph.D.
Executive Chair
Barry Greene
Director
Robert Nelsen, M.B.A.
Director
Saraswathy (Sara) V. Nochur, Ph.D.
Director
Ron Philip
Director
